VKTX missed EPS expectations by 23.90%
Apr 23, 2025, 10:35 PM
0.00%
What does VKTX do
Viking Therapeutics, based in San Diego, develops therapies for metabolic and endocrine disorders, including VK2809 for NASH, VK0214 for X-ALD, and VK2735 for metabolic issues. The company went public on April 29, 2015, and has 28 employees.
Viking Therapeutics (VKTX) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Viking Therapeutics's actual EPS was -$0.41, missing the estimate of -$0.33 per share, resulting in a -23.90% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.